Document Detail


Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort.
MedLine Citation:
PMID:  19627580     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Little is known about systemic B-cell activation in early rheumatoid arthritis (RA). We therefore evaluated the serum levels of markers of B-cell activation in patients included in the ESPOIR early arthritis cohort. METHODS: In the ESPOIR early arthritis cohort (at least 2 swollen joints for more than 6 weeks but less than 6 months), 710 patients were assessed at 1 year and either met the 1987 American College of Rheumatology criteria for RA (n = 578) or had undifferentiated arthritis (n = 132). Baseline serum samples of patients na??ve to corticosteroid and disease-modifying antirheumatic drug treatment were assessed for beta2-microglobulin, IgG, IgA, IgM, immunoglobulin free light chains of immunoglobulins, and B-cell activating factor of the tumor necrosis factor family (BAFF). The BAFF gene 871T>C polymorphism was genotyped in all patients. RESULTS: All markers of B-cell activation except BAFF and IgM were significantly higher in patients with early RA than those with undifferentiated arthritis. Anti-cyclic citrullinated peptide (anti-CCP) and beta2-microglobulin were associated with a diagnosis of early RA in the multivariate analysis. Markers of B-cell activation, except BAFF, were associated with disease activity, rheumatoid factor and anti-CCP secretion. The BAFF gene polymorphism was not associated with early RA. CONCLUSIONS: Markers of B-cell activation are elevated in patients with early RA, compared with undifferentiated arthritis, independently of any systemic increase in BAFF secretion, and correlate with disease activity. This study sheds new light on the early pathogenic role of B-lymphocytes in RA and suggests that targeting them might be a useful therapeutic strategy in early RA.
Authors:
Jacques-Eric Gottenberg; Corinne Miceli-Richard; B??atrice Ducot; Philippe Goupille; Bernard Combe; Xavier Mariette
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2009-07-23
Journal Detail:
Title:  Arthritis research & therapy     Volume:  11     ISSN:  1478-6362     ISO Abbreviation:  Arthritis Res. Ther.     Publication Date:  2009  
Date Detail:
Created Date:  2009-09-18     Completed Date:  2009-12-16     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101154438     Medline TA:  Arthritis Res Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  R114     Citation Subset:  IM    
Affiliation:
Rhumatologie, H??pitaux Universitaires de Strasbourg, Centre de R??f??rence National des Maladies Auto-Immunes Syst??mique Rares, EA 3432 Physiopathologie des Arthrites, Strasbourg, France. jegotten@club-internet.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Arthritis, Rheumatoid / blood*,  immunology
Autoantibodies / blood
B-Cell Activating Factor / blood*,  genetics
B-Lymphocytes / immunology*
Biological Markers / blood
Enzyme-Linked Immunosorbent Assay
Female
Humans
Lymphocyte Activation / immunology*
Male
Middle Aged
Chemical
Reg. No./Substance:
0/Autoantibodies; 0/B-Cell Activating Factor; 0/Biological Markers; 0/TNFSF13B protein, human
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: syne...
Next Document:  Effect of a 5000 ppm fluoride toothpaste and a 250 ppm fluoride mouth rinse on the demineralisation ...